All conditions

Alopecia Areata

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

579
Trials on record
78
Recruiting now
5
Australian sites
11
Phase 3 trials
2
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Alopecia Areata →

Get alerts when Alopecia Areata trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Alopecia Areata

Alopecia areata is a condition where the immune system mistakenly attacks the hair follicles, causing hair to fall out in patches. The hair loss can happen on the scalp, eyebrows, eyelashes, or other areas of the body. The follicles themselves are not permanently destroyed, which means hair can grow back, though this can vary a lot from person to person. The condition is not contagious and is not caused by anything you did or did not do.

In Australia, alopecia areata affects an estimated one in fifty people at some point in their lives, making it one of the more common autoimmune conditions in the country. It can affect people of any age, including children, and occurs across all backgrounds and ethnicities. Men and women are affected in roughly equal numbers. Some people experience a single episode with full regrowth, while others find the hair loss is more persistent or widespread over time.

When it comes to managing the condition, doctors and dermatologists have a range of options they may discuss with patients depending on factors like the extent of hair loss and the individual's circumstances. These can include topical, injectable, or oral medications aimed at calming the immune response and encouraging hair regrowth. Waiting and monitoring without active treatment is also a recognised approach in some cases. If you have questions about what might be appropriate for your situation, a GP or dermatologist is the best person to talk to, as they can take your full medical history into account.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Alopecia Areata in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Alopecia Areata

2 medicines listed on the PBS for Alopecia Areata. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 2 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
betamethasone acetate + betamethasone sodium phosphate Celestone Chronodose Alopecia areata AU$15.03 Restricted benefit
Triamcinolone Kenacort-A10 Alopecia areata AU$15.03 Restricted benefit

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Alopecia Areata currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Alopecia Areata.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Alopecia Areata by country. Australia is highlighted.

Showing the top 10 of 38 countries with trial sites.

Clinical trials for Alopecia Areata

Showing 82 of 82 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02974868 · Pfizer Phase 2 · 3 countries Completed
Completed Phase 2 Est. completion 15 May 2019
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) at the time you sign the consent form - You have been diagnosed with moderate to severe alopecia areata (a condition causing significant hair loss) **Who may not be able to join:** - You have HIV or tested positive for HIV duri...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04006457 · Pfizer Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 25 June 2024
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO🇨🇿 CZ🇩🇪 DE +9 more

**Who might be able to join this trial:** - You have been diagnosed with alopecia areata (a condition causing hair loss) and your hair loss is not caused by anything else — though having common pattern baldness alongside alopecia areata is acceptable. - If you are aged 12 to under 18, you have lost at least 50% of the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05589610 · Equillium Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 26 March 2024
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** - You have been diagnosed with alopecia areata (AA) as the only known reason for your hair loss - You have lost at least 35% of your scalp hair, as measured by a standard scoring tool called SALT, at the time of your screening and baseline visits - Your current episode of hair...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05723198 · Eli Lilly and Company Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇭🇺 HU🇯🇵 JP🇵🇱 PL +4 more

**Who might be able to join this trial:** - You are between 12 and 17 years old (note: younger children aged 6–11 may join after the older age group has been enrolled) - You have been diagnosed with severe alopecia areata (significant patchy hair loss) for at least 1 year - Your current episode of hair loss has been o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06012240 · AbbVie Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2030
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇳 CN +20 more

**Who might be able to join this trial:** - You must be an adult younger than 64 years old at the time of your first study visit (in some countries outside the US and EU, teenagers aged 12 and older may also be able to join certain parts of the study — check with the trial site). - You must have been diagnosed with se...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07205159 · Forte Biosciences, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 10 March 2027
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** - Men between the ages of 18 and 60, or women between the ages of 18 and 75, at the time of screening - People who have been diagnosed with severe or very severe alopecia areata, meaning they have lost at least 50% of the hair on their scalp (including those with complete scalp...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07317544 · Absci Pty Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇦🇺 AU

**Who might be able to join this trial:** - You must be generally healthy, based on a review of your medical history, a physical exam, and a heart tracing test (ECG) - Your blood tests, urine tests, and clotting tests must all come back within normal ranges - Your body mass index (BMI) must be between 18 and 32, and y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07327359 · Olix Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇦🇺 AU

**Who might be able to join this trial:** - You are an adult male. - You are between 18 and 59 years old. - You have been diagnosed with male-pattern baldness at a moderate to significant level (known as Hamilton-Norwood scale stages III to V — confirm with trial site if unsure of your stage). - Your body weight is at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05556265 · Bristol-Myers Squibb Phase 2 · 6 countries Terminated
Terminated Phase 2 Est. completion 6 January 2024
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇯🇵 JP🇵🇱 PL🇺🇸 US

Who might be able to join this trial: - You have been officially diagnosed with alopecia areata (a condition causing patchy hair loss) for at least 6 months. - Your current episode of hair loss on the scalp has been ongoing for at least 6 months. - Your current episode of hair loss covering 50% or more of your scalp ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04207931 · Wake Forest University Health Sciences Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are an African-American woman between 18 and 60 years old - You have been diagnosed with a specific type of hair loss called CCCA (Central Centrifugal Cicatricial Alopecia), confirmed by a skin biopsy, with a severity level between 1 and 4 on a standard scale - You are ab...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04594018 · EMS Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2026
🇧🇷 BR

**Who might be able to join this trial:** - You are able to give your voluntary agreement to take part by signing and dating a consent form - You are a man aged 18 to 60 years old who has been diagnosed with a specific level of male pattern baldness (grades IIIv to IV on the modified Norwood-Hamilton scale — confirm wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04764331 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a woman aged 18 or older who has been diagnosed with Central Centrifugal Cicatricial Alopecia (CCCA) at Stage II or III, confirmed by a skin biopsy. - You have been on a stable treatment plan for at least 3 months without any changes — this may include doxycycline (an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04764357 · St. Jude Children's Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are receiving chemotherapy that is known to cause hair loss (such as drugs like cyclophosphamide, doxorubicin, paclitaxel, docetaxel, or similar medications) - You have been diagnosed with a non-cancerous condition (such as Sickle Cell Disease or Aplastic Anemia) OR a so...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04986579 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman who has been diagnosed with breast cancer that has spread to other parts of the body (metastatic), and you are still able to carry out basic daily activities (confirm with trial site regarding activity level assessment) - You are 18 years old or older...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05177289 · Jessa Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇧🇪 BE

**Who might be able to join this trial:** - People who have been diagnosed with a gynaecological cancer (cancer of the uterus lining, cervix, ovaries, or vulva) or breast cancer - People who are currently receiving a chemotherapy treatment known as (Carbo)-Taxol - People who are 18 years of age or older - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05213936 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are female - Your natural hair type is curly (type 3) or kinky/coily (type 4) - You have been diagnosed with breast cancer, non-small cell lung cancer, or a gynecologic cancer (any stage from I to IV) - You are about to start at least 4 cyc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05398809 · National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** *For people with APECED-related hair loss (alopecia areata):* - The person must be able to understand the study and give their agreement to take part. - The person must be aged between 12 and 75 years old. - The person must have a diagnosis of APECED (confirmed by genetic tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05417308 · Ohio State University Comprehensive Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with breast cancer (any stage from I to IV) - You are currently taking hormone-blocking medication for breast cancer, such as tamoxifen or aromatase inhibitors, with or without medication to suppress ovary function -...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05460611 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - You are male or female, aged 18 or older, and are looking for treatment for hair loss - You have been diagnosed with androgenetic alopecia (common pattern baldness) or scarring alopecia, confirmed by a biopsy, with hair loss recorded over the past 6 months - Your hair loss tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05551793 · Emma Guttman Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman aged 18 or older. - You are able to understand the study and are willing to sign a consent form before taking part. - You are able to attend scheduled appointments and follow the study requirements. - If you are a woman who could become pregnant, you m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05745389 · CorEvitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2099
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with alopecia areata (a condition causing hair loss) by a dermatologist or qualified skin specialist. - You are 18 years of age or older. - You are willing to share your personal information as part of the registry. - You have been prescribed, or are j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05866562 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 6 and 17 years old, and a parent or legal guardian is able to sign the consent forms on your behalf. - You are able to attend all required study visits and follow the study schedule. - If you are a girl who could potentially become pregnant, you must have a n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05888922 · Industrial Farmacéutica Cantabria, S.A. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇩🇪 DE

**Who might be able to join this trial:** - Women aged 18 or older who are in generally good health, with no history of heart or cardiovascular conditions or other significant health problems - People diagnosed with female pattern hair loss (a visible thinning of hair in the top/centre of the scalp, rated at a certain...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05938569 · Venus Concept Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a man who has been diagnosed with male-pattern baldness, with a hair loss level rated between III and VI on the Norwood-Hamilton scale (a standard scale used to measure the extent of male hair loss) - You are between 20 and 70 years old - You are willing to have your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06046651 · Roman Health Ventures Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2033
🇺🇸 US

Who might be able to join this trial: - People of any gender who are in good general health - People who are 18 years old or older at the time of joining - People who are willing to provide small blood samples, either by a fingerprick on the finger or from a vein, including collecting some samples themselves at home -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06104839 · NEXTGEN Bioscience Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇰🇷 KR

**Who might be able to join this trial:** - You are a man or woman aged 19 to 65 years old at the time of signing consent - You have moderate to severe alopecia areata (patchy hair loss), with between 25% and 94% of your scalp affected by hair loss, as measured at your screening visit and first study visit - Your curre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06283316 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2099
🇳🇱 NL

Who might be able to join this trial: - You have been diagnosed with alopecia areata (a condition that causes patchy hair loss) - You are starting or already using a treatment that works throughout the whole body (such as a pill or injection) for your alopecia areata - You (and/or your caregiver, if applicable) have ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06327581 · Zagazig University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 16 years old or older and have patchy hair loss (alopecia areata) in a limited area (no larger than about 6 cm across) - You can be of any sex - You are willing to take part in the study and sign a consent form agreeing to participate **Who may not be able to join:**...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06360718 · Children's Hospital Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are the parent or legal guardian of a child aged 3 to 16 years old who has just been diagnosed with leukemia - You are the parent or legal guardian of a child younger than 3 or older than 16 who has just been diagnosed with leukemia, AND that child has a sibling who is be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512753 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a condition called lichen planopilaris (LPP), a type of scarring hair loss - You are willing to sign a consent form agreeing to take part in the study - You do not have any known allergies or medical reasons that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06531109 · Pfizer Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 15 April 2028
🇨🇳 CN🇫🇷 FR🇮🇹 IT🇯🇵 JP🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are male or female and older than 12 years of age - You have been diagnosed with alopecia areata (a condition causing hair loss) by a certified skin doctor, and your doctor has already prescribed you a medication called ritlecitinib as part of your normal treatment - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06560385 · GenieBiome Limited Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 August 2025
Hong Kong

**Who might be able to join this trial:** - You are a woman between 18 and 60 years old who has recently been diagnosed with stage I, II, or III breast cancer - You are planned to receive chemotherapy containing a specific type of drug (called an anthracycline or taxane), and this treatment will be finished within 6 mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562270 · CorEvitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2099
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe alopecia areata (a condition causing significant hair loss) by a skin doctor or qualified skin care provider at some point in your life. - You are between 12 and 17 years old at the time of joining the registry. - You are willing to agree t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06564805 · Universidad Autonoma de Nuevo Leon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇲🇽 MX

**Who might be able to join this trial:** - You have been diagnosed with alopecia areata (a condition that causes patchy hair loss) - Less than 50% of your scalp is affected by hair loss (based on a standard measurement called the SALT score) - You have not used any hair loss treatments — either on your skin or taken b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06573593 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 2 and 18 years old and have been diagnosed with alopecia areata (a condition that causes hair loss) - You have been formally diagnosed with alopecia areata following standard medical guidelines - You have been taking one of the following medications for more t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06603194 · Ancient + Brave Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 November 2024
🇬🇧 GB

**Who might be able to join this trial:** - You are a woman between the ages of 35 and 55 years old. - You are comfortable using collagen products made from animal sources (beef or fish), meaning this trial is not suitable for vegans or vegetarians. - You are willing to give your agreement to take part and follow the s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06747611 · University of Minnesota Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old and have moderate to severe hair loss from alopecia areata (affecting more than 30% of the scalp). - You have been diagnosed with patch-type alopecia areata, alopecia totalis, or alopecia universalis. - Your hair loss has been present for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06786078 · Luminate Medical, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years or older and have been diagnosed with stage 1, 2, or 3 breast cancer - Your doctor has decided that chemotherapy before or after surgery is the right treatment for you, and you have not yet started any cancer treatment - You are scheduled to receive at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06818370 · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospita... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with breast cancer. - People whose planned chemotherapy treatment is the Doxorubicin-Cyclophosphamide protocol. - People who are willing to take part in the study. - People who are 18 years of age or older. - People who are women. Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06826196 · Aldena Therapeutics Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 55 years at the time of giving consent - People with a body mass index (a measure of body weight relative to height) between 18.0 and 35.0, and a body weight of at least 50 kg, at the screening visit - People with a clinically confirmed diagnosis of alopeci...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06841458 · Industrial Farmacéutica Cantabria, S.A. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇪🇸 ES

**Who might be able to join this trial:** - You must be willing to sign a written agreement to follow the study rules (compliance consent). - You must be willing to sign a written informed consent form for this specific study. - You must be male. - You must be between 18 and 45 years old. - You must have been diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06869252 · CERM INC. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇺🇸 US

Who might be able to join this trial: - People who are interested in improving the appearance of their skin, or who have skin concerns such as wrinkles, fine lines, loss of skin firmness, uneven skin tone, or scarring - People who are experiencing hair loss or thinning hair - People who are willing to sign and date a c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06885112 · Lumenis Be Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 21 and 55 years old (inclusive) - You have a darker skin tone, classified as Fitzpatrick Skin Type V or VI (confirm with trial site) - You have mild to moderate hair loss or thinning (as assessed by the trial team using standard hair loss scales) - You have n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06946550 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a male or female aged 18 or older who is looking for treatment for scarring hair loss - You are able to read, understand, and sign a consent form agreeing to take part - You have been diagnosed with scarring hair loss either through a skin biopsy or by a dermatologist...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06955702 · University of Salamanca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been recently diagnosed with breast cancer (at any stage) - You are planned to receive a type of chemotherapy that includes drugs known as anthracyclines and/or taxanes as your first treatment - You have not received any cancer trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06998680 · Vita Green Pharmaceutical (H.K.) Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing to sign a consent form showing you understand the study's purpose, what it involves, and possible side effects - You must be between 18 and 60 years old (men and women are both eligible, and at least half of each group must be women) - Your hair must be lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07012486 · Shanghai Zhongshan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 May 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed by a doctor with common pattern hair loss (the type caused by genetics, sometimes called male or female pattern baldness) - You do not plan to become pregnant in the next 6 months Who may not be able to join: - You have taken any medication by mouth or in...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07023302 · AbbVie Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇯🇵 JP

**Who might be able to join this trial:** - The trial doctor has reviewed your health history and screening results and considers you to be in good health. - You have been diagnosed with severe alopecia areata (a condition causing significant hair loss) with at least 25% of your scalp hair lost, confirmed at both your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07029204 · University of California, Davis Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old at the time of your screening appointment - A qualified skin doctor (dermatologist) has diagnosed you with alopecia areata at your screening appointment - Your current episode of alopecia areata has been affecting your scalp for more than 3...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07029828 · Pfizer Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 26 June 2030
🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇯🇵 JP🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - You previously completed one of two related studies (called B7981027 or B7981031) for a hair loss condition called alopecia areata (which includes total scalp hair loss or full body hair loss). - If you came from the study called B7981031, you must have had at least 50% scal...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07033845 · Applied Biology, Inc. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 19 October 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are a healthy woman between the ages of 18 and 55 - Your body mass index (BMI) falls between 18 and 30 (a standard measure of body weight relative to height) - Your skin tone falls within a light to medium range on a standard skin classification scale known as Fitzpatrick...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07041489 · The Center for Clinical and Cosmetic Research Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 March 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 28 and 65 years old who feels your hair has been consistently getting thinner - A doctor has assessed your hair loss as mild to moderate (using a standard hair loss scale called the Ludwig Scale, levels I or II) - You have any skin tone (all skin types...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07049328 · HCW Biologics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 16 July 2026
🇺🇸 US

**Who might be able to join this trial:** - Women between 18 and 70 years old, or men between 18 and 60 years old at the time of signing up for the trial - People who have been diagnosed with Alopecia Areata (AA), including specific types called ophiasis, totalis, or universalis - Women who could become pregnant must...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07079657 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇩🇪 DE

Who might be able to join this trial: - You are a man or woman aged 18 or older - You are in good general health with no significant past illnesses - You have been diagnosed with androgenetic alopecia (a common type of hair loss also known as male or female pattern baldness) - You are able to understand the study and a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07080931 · Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and able to sign a consent form agreeing to join the study - You are a woman aged 18 or older - You have been diagnosed by a doctor with female pattern hair loss (androgenetic alopecia) - Your hair loss falls within a moderate-to-severe range on a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07107841 · Acorn Biolabs Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old (male or female). - You have been diagnosed with androgenic alopecia (common pattern hair loss/baldness). - If you are male and currently taking minoxidil (oral or topical) and/or a 5-alpha reductase inhibitor (a type of hair loss medicati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07133308 · Sun Pharmaceutical Industries, Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 May 2028
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with alopecia areata (a condition causing patchy hair loss), and your current episode has been ongoing for at least 6 months but no longer than 10 years - You are between 12 and 17 years old - You have lost at least 50% of the hair on your scalp, as me...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07146022 · Veradermics, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 18 and 65 years old - You have been diagnosed by a doctor with mild to moderate androgenetic alopecia (a common type of hair thinning or hair loss) - You are in good overall health, with kidneys and liver that are working well - You are willing to keep...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07152119 · Pfizer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 March 2030
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with severe alopecia areata (a condition causing significant hair loss) and your doctor has already decided that you should be treated with Litfulo (ritlecitinib) capsules based on its approved use - You are an adult or a young person aged 12 years or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07203599 · Shenzhen People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a male between the ages of 18 and 35 - You have been diagnosed by a doctor with male-pattern baldness (androgenic alopecia) at a moderate to moderately severe level (Hamilton Norwood Scale III–V) - You are willing to take part voluntarily and are able to sign a consen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07242638 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 12 years old, with a parent or legal guardian able to sign consent forms on their behalf before the trial begins. - People who have been diagnosed with Trisomy 21 Down Syndrome (note: translocation or mosaic Down Syndrome is listed separately as an ex...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07311564 · Almirall, S.A. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman between 18 and 65 years old at the time of signing the consent form. - You have lost 50% or more of the hair on your scalp, with no signs of new terminal hair growing back, as confirmed at both your screening and first study visits. - Your current episo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07335367 · Nanfang Hospital, Southern Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a common type of hair loss (androgenetic alopecia) confirmed by your medical history, appearance, and a scalp examination, at a moderate to significant level of hair loss - You are willing to take part in the study and have agreed to do so in writ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07340671 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 April 2027
🇺🇸 US

Who might be able to join this trial: - People of any gender aged 18 or older - People with any skin tone (Fitzpatrick Skin Types I through VI are all included) - People who have been clinically diagnosed with FFA (frontal fibrosing alopecia) with small bumps on the face (facial papules) - People who are able to read,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07368842 · Singapore General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇸🇬 SG

**Who might be able to join this trial:** *For all participants:* - You are between 21 and 70 years old - You are able to read, understand, and sign a consent form agreeing to take part *For the healthy weight group:* - Your BMI (a measure of body weight relative to height) falls between 18.5 and 24.9, which is consi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07370519 · Shenzhen People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a common type of hair loss (known as pattern baldness) confirmed by your medical history, appearance, and a scalp examination, and your hair loss falls within a mild-to-moderate range on standard grading scales - You are willing to take part and h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07373054 · Fujian Medical University Union Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are male and between 18 and 60 years old (inclusive), and are generally in good health. - You have been diagnosed with male-pattern hair loss (the most common type of baldness in men) following specific Chinese clinical guidelines, your hair loss has been happening for le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07381556 · Erasmus Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2027
🇳🇱 NL

Who might be able to join this trial: - Children and teenagers between 2 and 17 years old - People who have been diagnosed with alopecia areata (a condition causing hair loss) by a qualified skin specialist (dermatologist) - For participants aged 12–17, both the young person and their parents or guardians must be willi...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07422376 · Charles Mays Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage I, II, or III breast cancer - You are aged 18 years or older - You are planned to receive chemotherapy that includes a type of drug called an anthracycline or a taxane - You are willing and able to give your consent to take part (participati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07429253 · PT. Prodia Stem Cell Indonesia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇮🇩 ID

**Who might be able to join this trial:** - Men aged 25 to 59 years who have a common pattern of hair loss (male-pattern baldness) that falls within a certain range of severity, and who are being seen at the Dermatology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. - Women aged 25 to 59 years who ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07435012 · Triple Hair Inc Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇦 CA

Who might be able to join this trial: - You are male and between 18 and 49 years old at the time of enrolling in the trial. - You have a certain level of male pattern hair loss, rated between "III vertex" and "V" on a standard hair loss scale (confirm with trial site). - Your body weight falls within a healthy-to-moder...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07487948 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 5 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing up for the study, of any gender. - People who are willing and able to attend scheduled study visits and follow the study's requirements. - People who report having had a type of scarring hair loss (specifically lichen planopilar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07502976 · Kasr El Aini Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇪🇬 EG

Who might be able to join this trial: - You are between 18 and 50 years old. - You are a man or woman experiencing common pattern hair loss (the type caused by genetics and hormones). - Your hair loss is mild to moderate in severity, based on standard hair loss rating scales used by doctors (confirm with trial site). -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07508488 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing up for the study. - People who are willing and able to attend scheduled study visits and follow the study requirements. - People who report having moderate-to-severe scarring hair loss (specifically FFA or CCCA) for at least 6 m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07533006 · Eli Lilly and Company Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇦 CA🇨🇳 CN🇳🇱 NL🇵🇱 PL🇰🇷 KR🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe Alopecia Areata (a condition causing significant hair loss on the scalp) - Your hair loss covers between 50% and 90% of your scalp, as measured by a standard hair loss scoring tool - Your current episode of severe hair loss has been going...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07536100 · Institute of Dermatology, Thailand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇹🇭 TH

**Who might be able to join this trial:** - You are 18 years old or older (any gender) - You have been diagnosed with a specific type of hair loss called androgenetic alopecia (pattern baldness), at a moderate stage — rated III to V on the male scale, or I to II on the female scale - You are able to read and write well...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563036 · Kasr El Aini Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are a male between 18 and 50 years old with male-pattern baldness (the common type of hair loss in men) - Your hair loss is mild to moderate in extent (confirm with trial site) - You have never used hair loss treatments before, or you are willing to stop any current hair...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07588243 · CynosureLutronic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 22 and 70 years old - You are willing to use the study device as required - You have any skin tone or complexion (all skin types are welcome) - You have been diagnosed by a doctor with common pattern hair loss (the type that runs in families, affecting the hai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07603544 · The First Affiliated Hospital of Xinxiang Medical College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a male between the ages of 25–30 or 60–65 years old - You have been diagnosed by a doctor with a specific stage of male-pattern hair loss (called Hamilton-Norwood Stage III), OR you have a healthy scalp with no signs of hair loss (for the healthy comparison group) - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07617597 · Sun Pharma Japan Limited Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇯🇵 JP

**Who might be able to join this trial:** - You have agreed to take part and signed a consent form. - You are Japanese, aged between 18 and 65 years old at the time of signing the consent form, and have severe alopecia areata (significant hair loss condition). - You have been officially diagnosed with alopecia areata a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07618195 · Epibiotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇰🇷 KR

Who might be able to join this trial: - You are 19 years old or older - You have been diagnosed with androgenetic alopecia (a common type of hair loss sometimes called male or female pattern baldness) - You are willing to keep the same hairstyle, hair length, and hair color throughout the study - You are willing to avo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07693244 · Zhang Han Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - Men between 18 and 55 years of age - People diagnosed with male-pattern baldness rated at a specific severity level known as Norwood-Hamilton grade III, IV, or V (confirm with trial site for clarification on grading) - People whose hair loss pattern has remained stable for at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Alopecia Areata. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Australia Alopecia Areata Foundation is the national body supporting people with alopecia areata.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.